Omep Uno (Omeprazole)

Omeprazole, the active ingredient in Omep Uno, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omep Uno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.

Adverse reactions to omeprazole are generally mild to moderate, but serious events can occur.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild discomfort in the upper abdomen. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hypomagnesemia: low magnesium levels with prolonged use. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term therapy.

When prescribing omeprazole, clinicians should consider several safety aspects. - Assess renal and hepatic function: adjust use in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for nutrient deficiencies (e.g., B12, magnesium). - Counsel pregnant or breastfeeding patients: weigh benefits against potential risks. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral exposure, compromising HIV therapy. - Dasatinib: lowered plasma concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Phenytoin: may reduce phenytoin levels, necessitating dose adjustment. - Methotrexate: increased systemic exposure, especially at high doses.